Dr. Abdul Khader Mohammad is a Principal Scientist, Formulation Development, CMC, at Denali Therapeutics based in South San Francisco. He has previously worked for companies such as Pharmaceutics International Inc. and Achaogen Inc. where he held positions of increasing responsibility. His graduate research was centred around understanding the in-vivo distribution of polymeric nanoparticles after pulmonary administration as well as studying the in-vivo distribution and simultaneous degradation of degradable polymeric nanoparticles after intravenous administration. This study was the first in the field and was widely acknowledged in the circles of drug delivery. He is currently on the Editorial Board for World Journal of Pharmaceutical Research and Journal of Pharmaceutical Research and Therapeutics while also serving as a reviewer for esteemed pharmaceutical journals such as Journal of Controlled Release, Molecular Pharmaceutics, International Journal of Pharmaceutics, European Journal of Pharmaceutical Sciences, and European Journal of Pharmaceutics and Biopharmaceutics to name a few.
Dr. Mohammadís area of interests include multi-particulate drug delivery systems, combination therapy formulation development, controlled release drug delivery systems, delayed released drug delivery systems, amorphous solid dispersions, pre-clinical research, early phase product development, late stage product development and commercialization, and nanotechnology.